TNSN86004A1 - Compose pharmaceutiquement actif et procede pour sa preparation - Google Patents

Compose pharmaceutiquement actif et procede pour sa preparation

Info

Publication number
TNSN86004A1
TNSN86004A1 TNTNSN86004A TNSN86004A TNSN86004A1 TN SN86004 A1 TNSN86004 A1 TN SN86004A1 TN TNSN86004 A TNTNSN86004 A TN TNSN86004A TN SN86004 A TNSN86004 A TN SN86004A TN SN86004 A1 TNSN86004 A1 TN SN86004A1
Authority
TN
Tunisia
Prior art keywords
preparation
active compound
pharmaceutically active
treatment
compounds
Prior art date
Application number
TNTNSN86004A
Other languages
English (en)
Inventor
Rosen Borje
Leander Kurt
Original Assignee
Conpharm Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conpharm Ab filed Critical Conpharm Ab
Publication of TNSN86004A1 publication Critical patent/TNSN86004A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES CONSISTANT EN PODOPHYLLOTOXINE ET EN SES DERIVES DE FORMULE (I). DANS LAQUELLE R1 REPRESENTE H OU OH ET R2 REPRESENTE H OU CH3, POUR LE TRAITEMENT DE CERTAINS ETATS PATHOLOGIQUES, ET UN PROCEDE PERMETTANT DE LES OBTENIR. L'INVENTION CONCERNE EN OUTRE L'UTILISATION DES COMPOSES POUR LE TRAITEMENT DES DITS ETATS PATHOLOGIQUES AINSI QUE L'UTILISATION DES DITS COMPOSES POUR LA PREPARATION DES COMPOSITIONS PHARMACOLOGIQUES DESTINEES AU TRAITEMENT DES DITS ETATS PATHOLOGIQUES
TNTNSN86004A 1984-12-28 1986-01-09 Compose pharmaceutiquement actif et procede pour sa preparation TNSN86004A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8406660 1984-12-28

Publications (1)

Publication Number Publication Date
TNSN86004A1 true TNSN86004A1 (fr) 1990-01-01

Family

ID=20358339

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN86004A TNSN86004A1 (fr) 1984-12-28 1986-01-09 Compose pharmaceutiquement actif et procede pour sa preparation

Country Status (23)

Country Link
US (1) US4788216A (fr)
EP (1) EP0207124B1 (fr)
JP (2) JPH0720966B2 (fr)
CN (1) CN1006795B (fr)
AP (1) AP32A (fr)
AT (1) ATE68186T1 (fr)
AU (1) AU585936B2 (fr)
CA (1) CA1255230A (fr)
DE (1) DE3584370D1 (fr)
DK (1) DK169506B1 (fr)
DZ (1) DZ876A1 (fr)
EG (1) EG17788A (fr)
ES (1) ES8701761A1 (fr)
FI (1) FI89330C (fr)
GR (1) GR853145B (fr)
HU (1) HU201672B (fr)
IL (1) IL77456A (fr)
MA (1) MA20602A1 (fr)
NO (1) NO863329D0 (fr)
PT (1) PT81760B (fr)
TN (1) TNSN86004A1 (fr)
WO (1) WO1986004062A1 (fr)
ZA (1) ZA859881B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644072A (en) * 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
DE69033342T2 (de) * 1989-02-23 2000-05-11 University Of North Carolina At Chapel Hill, Chapel Hill Etoposidanaloge
SE464167B (sv) 1989-07-31 1991-03-18 Analytecon Sa Topisk farmaceutisk beredning av podophyllotoxin
US5332811A (en) * 1989-09-12 1994-07-26 The University Of North Carolina At Chapel Hill Etopside analogs
US5338867A (en) * 1992-04-24 1994-08-16 Genelabs Technologies, Inc. Preparation of 4β- amino podophyllotoxin compounds
SE9301831D0 (sv) * 1993-05-28 1993-05-28 Analytecon S A Pharmaceutical compositions
GB9422947D0 (en) * 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
US6051721A (en) * 1997-10-02 2000-04-18 The Board Of Regents Of The University Of Nebraska Ring E-modified analogues of(-)-podophyllotoxin and etoposide and a method for their synthesis
FI105152B (fi) 1998-07-17 2000-06-30 Eero Saarela Paikallinen kivunlievitysmenetelmä
US6143304A (en) * 1999-08-17 2000-11-07 The University Of Mississippi Enhanced yield of podophyllotoxin from natural products through in situ conversion methods
KR20040030686A (ko) * 2001-06-19 2004-04-09 악셀라르 아베 시클로리그난의 신규의 용도 및 신규의 시클로리그난
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
US20110178050A1 (en) * 2008-06-23 2011-07-21 Axelar Ab Use of cyclolignans for the treatment of a hyperactive immune system
EP2817007A1 (fr) * 2012-02-24 2014-12-31 Nestec S.A. Peltatine destinée à être utilisée pour traiter des troubles inflammatoires chroniques
WO2015028456A1 (fr) * 2013-08-28 2015-03-05 Nestec S.A. Modulateurs des rapp
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA635769A (en) * 1962-01-30 Rutschmann Jurg Amides of podophyllic acid and picropodophyllic acid
SE335139B (fr) * 1964-08-12 1971-05-17 Sandoz Ag
US4122092A (en) * 1977-08-25 1978-10-24 University Of Rochester Total synthesis of (±)-picropodophyllone and (±)-4'-demethylpicropodophyllone
US4567253A (en) * 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
GB8424269D0 (en) * 1984-09-26 1984-10-31 Pharma Medica As Isolation and purification of podophyllotoxin

Also Published As

Publication number Publication date
FI89330C (fi) 1993-09-27
AU5300386A (en) 1986-07-29
EP0207124B1 (fr) 1991-10-09
AP8500017A0 (en) 1985-11-01
NO863329L (no) 1986-08-19
ATE68186T1 (de) 1991-10-15
DK408186D0 (da) 1986-08-27
ES8701761A1 (es) 1986-12-01
HU201672B (en) 1990-12-28
FI863482A (fi) 1986-08-27
CN1006795B (zh) 1990-02-14
JPH0720966B2 (ja) 1995-03-08
AP32A (en) 1988-12-07
GR853145B (fr) 1986-04-29
DE3584370D1 (de) 1991-11-14
CN85109666A (zh) 1986-10-29
WO1986004062A1 (fr) 1986-07-17
PT81760B (pt) 1987-11-11
HUT47582A (en) 1989-03-28
IL77456A (en) 1989-07-31
US4788216A (en) 1988-11-29
DK169506B1 (da) 1994-11-14
FI863482A0 (fi) 1986-08-27
AU585936B2 (en) 1989-06-29
MA20602A1 (fr) 1986-07-01
DK408186A (da) 1986-08-27
EG17788A (en) 1990-12-30
JPS62501360A (ja) 1987-06-04
FI89330B (fi) 1993-06-15
DZ876A1 (fr) 2004-09-13
NO863329D0 (no) 1986-08-19
CA1255230A (fr) 1989-06-06
IL77456A0 (en) 1986-08-31
ZA859881B (en) 1986-09-24
JPH07173063A (ja) 1995-07-11
JP2572558B2 (ja) 1997-01-16
ES550504A0 (es) 1986-12-01
PT81760A (en) 1986-01-02
EP0207124A1 (fr) 1987-01-07

Similar Documents

Publication Publication Date Title
TNSN86004A1 (fr) Compose pharmaceutiquement actif et procede pour sa preparation
TNSN97070A1 (fr) Derives d'imidazole substitues, procede pour leur preparation, et compositions les contenant
YU48323B (sh) Postupak za dobijanje askorbinske kiseline
PT99109A (pt) Processo para preparacao de intermediarios de 9-metil(substituido)-10-hidroxi ou alcoxi-11-hidro ou alcoxi 1-6camptotecina soluveis em agua, para preparacao destas comptotecinas, sua purificacao e isolamento, e preparacao de composicoes farmaceuticas
FR2446289A1 (fr) Compose de 2-penem, procede de preparation et composition pharmaceutique obtenue
YU72303A (sh) Postupak za dobijanje (-)-4-amino-5-fluoro-1- (2-hiroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona
FR2407926A1 (fr) Derives de quinazoline, leur procede de production et composition pharmaceutique les contenant
FR2397403A1 (fr) Nouveaux derives de 1-acyl 2-cyano-aziridine, procede pour leur preparation et compositions pharmaceutiques contenant ces composes
TNSN99013A1 (fr) Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
BE901301A (fr) 5-pyrimidine-carboxamides et thiocarboamides, ainsi que le traitement de la leucemie et des tumeurs avec ces substances.
ES8400417A1 (es) "procedimiento para la preparacion de esteres carboxilicos de 6-hidroxi-2-benzotiazolsulfonamida".
FR2418789A1 (fr) Nouveaux sels de guanidine, procede permettant leur production et preparations microbicides les contenant
FR2446829A1 (fr) Derives de polymethylene disubstitues en alpha, omega, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2395272A1 (fr) Nouveaux medicaments derives de l'acide amidinopenicillanique
IT8420358A0 (it) Procedimento di preparazione di derivati 1-carbamoilmetilici di 4-idrossi-2-osso-pirrolidina nonche' di intermedi per ottenere tali composti.
BE893492A (fr) Procede de preparation d'esters d'acides apovincaminiques, esters ainsi obtenus et compositions pharmaceutiques prepares avec ces esters
FR2601680B1 (fr) Inhibiteur de la synthese proteique, procede d'isolement, utilisation et compositions pharmaceutiques en contenant
FR2653771B1 (fr) Procede de preparation de l'azt (azido-3'-desoxy-3'-thymidine) et de composes apparentes.
FR2416013A1 (fr) Derives d'acide (-)-(cis)-1,2-epoxypropylphosphonique, leur preparation et compositions pharmaceutiques les contenant
FR2506766A1 (fr) Sel de l-lysine ou de dl-lysine de l'acide 5-(p-chlorobenzoyl)-1,4-dimethylpyrrole-2-acetique, son procede de preparation et composition analgesique le contenant
TNSN86056A1 (fr) Procede de preparation de derives d'azetidine
FR2376863A1 (fr) Determination du 1a,25-dihydroxycholecalciferol
FR2409267A1 (fr) Derives de 4-amino-2-piperidinoquinazoline, leur procede de production et composition pharmaceutique les contenant
FR2592043A1 (fr) 2-chloro-12-(3-dimethylamino-2-methylpropyl)-12h-dibenzo-(d, g) (1, 3, 6)-dioxazocines optiquement actives, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2372145A1 (fr)